A drug-resistant fungus called Candida auris has been identified in 27 states across the US this year, with over 7,000 infections reported, according to the Centers for Disease Control and Prevention (CDC). Public health officials warn that the numbers are still climbing, highlighting the fungus as a significant risk in hospitals and long-term care facilities.
The CDC expresses concern over the fungus due to its resistance to multiple antifungal treatments, leading to severe and sometimes deadly illnesses. Those most vulnerable include patients with weak immune systems, those in intensive care, and individuals using medical devices like catheters or ventilators.
Interestingly, while this current increase seems especially prevalent in the United States, experts are increasingly worried about the global escalation of drug-resistant fungal infections. The spread of Candida auris is seen as part of a broader challenge that health systems worldwide face, including those in Europe and the UK.
Understanding Candida auris
Candida auris is a type of yeast responsible for invasive infections, such as those affecting the bloodstream, wounds, and ears. First detected in 2009, it has since appeared in many countries, primarily impacting individuals who are already in critical health.
The CDC has flagged C. auris as an urgent antimicrobial resistance threat. It’s particularly alarming because it can transmit easily in healthcare settings and can survive on surfaces and equipment for extended periods, complicating efforts to manage outbreaks.
Reported Cases in 27 States
Data from late 2025 indicates that Candida auris has appeared in 27 states this year, with over 7,000 cases marking a significant rise compared to previous years, underlining its expanding presence.
Health authorities explain that this number consists of both clinical infections, where patients show symptoms, and colonization cases, where the fungus is present but not symptomatic. It’s worth noting that even colonized individuals can transmit the fungus, particularly in healthcare environments.
The primary transmission routes have been healthcare facilities, where at-risk patients may be exposed. To minimize future outbreaks, state health departments and the CDC are advising hospitals to tighten infection control measures.
Concerns Among Health Officials
The NHS points out that Candida auris is particularly tricky to manage. Its various strains resist multiple antifungal medications, and some do not respond to any current treatments, leaving healthcare providers with limited options.
Diagnosing the infections can be delayed since standard tests may not accurately identify the fungus. Moreover, C. auris can linger on surfaces for several weeks, which raises the risk of ongoing outbreaks in hospitals and nursing homes. The link between invasive infections and high mortality rates among critically ill patients is particularly concerning.
A Broader Warning on Antifungal Resistance
The rise of Candida auris is indicative of a larger trend in antifungal resistance, according to the CDC. They attribute this problem to overuse and misuse of antifungal medications in both healthcare and agricultural contexts.
Healthcare providers are being urged to adhere to strict infection control guidelines, which include enhanced cleaning, proper hand hygiene, and isolating patients when needed. With cases on the rise, ongoing monitoring and prevention strategies will be crucial to mitigate one of the most challenging drug-resistant pathogens in recent years.
